Advanced Circulatory Selects Combat Medical Systems As Its Exclusive Sales Distributor for Military and Federal Market in US

MINNEAPOLIS, July 16, 2013 /PRNewswire/ -- Advanced Circulatory, manufacturer of multiple medical devices and the pioneer of Perfusion on Demand™ (POD) therapy, has selected Combat Medical Systems as its U.S. distributor for the military and federal market space. Combat Medical Systems will spearhead sales and distribution of Advanced Circulatory's products, including the ResQPOD^® and ResQGARD^® Impedance Threshold Devices (ITDs), to all branches of the U.S. military and federal government.

Combat Medical Systems was founded by a team of military medical personnel and industry specialists with a goal to simplify tactical medicine and decrease pre-hospital mortality. Combat Medical Systems is located outside Fort Bragg, N.C., which strategically positions the company to stay current on military medical trends.

"We are pleased to partner with Advanced Circulatory to make its products available to our military customers. Both the ResQPOD and ResQGARD support our desire to have a direct effect on battlefield casualty outcomes and provide superior products that simplify tactical medicine," noted Michael Langley, Combat Medical Systems' Director of Navy and Marine Corps Programs.

"We selected Combat Medical Systems as our exclusive U.S. military distributor due to its extensive depth of experience and proven track record in working with the federal government and the U.S. military," commented Mike Black, Advanced Circulatory's CEO.

Advanced Circulatory's ResQPOD and ResQGARD ITDs deliver POD therapy - a therapy with far reaching implications for multiple medical conditions - by enhancing perfusion non-invasively. The therapy increases circulation, protecting the heart, brain and other vital organs when blood flow is compromised, giving rescuers, clinicians and caregivers the potential to return patients to a full life after critical medical emergencies. When used in patients in shock, studies have shown that the ResQGARD ITD safely increases blood pressure up to 30%.^1-3  In addition, studies have shown the ResQPOD ITD increases the rate of neurologically-intact survival of cardiac arrest by 25% or more when compared to conventional CPR alone.^4-8 

Advanced Circulatory manufactures and markets the ResQPOD and the ResQGARD Impedance Threshold Devices in more than 25 countries worldwide.

Studies available upon request. The generally cleared indication for the ResQPOD and ResQGARD ITDs available for sale in the United States (US) is for a temporary increase in blood circulation during emergency care, hospital, clinic, and home use. Research is ongoing in the US to evaluate the long-term benefit of the ResQPOD and ResQGARD for other specific indications. The studies referenced here are not intended to imply specific outcomes-based claims not yet cleared by the US FDA.

SOURCE Advanced Circulatory